Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2021 15:29 ET | Source: United States Small Business Administration

SBA Re-Opens PPP to Community Financial Institutions First

Washington, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The U.S. Small Business Administration, in consultation with the U.S. Treasury Department, re-opened the Paycheck Protection Program (PPP) loan portal...
July 15, 2019 06:00 ET | Source: Capricor Therapeutics, Inc.

Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy

--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled...
August 21, 2018 07:00 ET | Source: Capricor Therapeutics, Inc.

Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles

LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the...
August 09, 2018 16:00 ET | Source: Capricor Therapeutics, Inc.

Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
May 03, 2018 07:00 ET | Source: Capricor Therapeutics, Inc.

Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal

LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at...
April 30, 2018 07:00 ET | Source: Capricor Therapeutics, Inc.

Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy

LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test...
April 19, 2018 07:00 ET | Source: Capricor Therapeutics, Inc.

Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model

LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an...
February 22, 2018 13:23 ET | Source: Capricor Therapeutics, Inc.

New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy

LOS ANGELES, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced the online publication in Stem Cell Reports of a new study by researchers at the Smidt Heart...